The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
273 - Hi, I will be following PAAB regulations to ensure that an unbranded disease information piece qualifies as being 'PAAB exempt'. I will also be submitting it to PAAB (simply to get a letter saying that it is PAAB exempt). Is it necessary that the review papers we are referencing DO NOT make mention of treatement options anywhere as well (even though our APS will not make mention of treatment options/categories)? Or is it ok if the review paper discusses treatments so long as we don't make mention of them in the APS?
-
The primary purpose of the review paper should not be to discuss treatment options. If it is then the APS you create could be deemed "editorial" in nature and subject to PAAB review. What is your intent? You should try to find a reference that discusses the disease only, not focussed on treatments. It may be exempt if all the treatments are balanced, see the Health Canada document The DIstinction Between Advertising and Other Activities 'Consumer Brochure'.
